Peer Review
Development and Validation of RP-HPLC Method for the Determination of Anticancer Drug Brigatinib
Khurshid Alam,Md. Rafiquzzaman +1 more
Reads0
Chats0
TLDR
In this article , the authors aimed to develop and validate RP-HPLC method for determination of brigatinib, which is the recent INN drug which belongs to second generation of tyrosine kinase inhibitor and indicated for non-small cell lung cancer.Abstract:
Now-a-days, one of the most devastating and life-threatening disorders is cancer. Various types of cancer based on the organ affected are namely lung cancer, breast cancer, stomach cancer, colon cancer etc. A number of anticancer drugs are obtainable among which tyrosine kinase inhibitor is the superior one. The available tyrosine kinase inhibitors are namely Crizotinib, Ibrutinib, Osimertinib, Brigatinib. Among them, brigatinib is the recent INN drug which belongs to second generation of tyrosine kinase inhibitor and indicated for non-small cell lung cancer. Literature review shows that there are no developed methods available for determination of brigatinib except UPLC method. In the present study, authors aimed to develop and validate RP-HPLC method for determination of brigatinib. Regarding RP-HPLC method, C18 column (ID: 5 micron*100 Å) was employed as stationary phase while combination of methanol and distilled water (75%:25%) was used as mobile phase. The retention time of brigatinib was found 5.6 min from the chromatogram. The regression equation was y = 53344x - 239.6 with coefficient of determination (R 2 ) 0.999 and correlation coefficient (r) 0.9994; indicating excellent linearity of the calibration curve obtained by the newly developed method. Percent (%) RSD for robustness, ruggedness, precision was below 2. Limit of detection and limit of quantification were found to be 0.332 μg/mL and 1.00 μg/mL, respectively. The findings ensure the suitability of the developed method as an established one to assay brigatinib in any quality control laboratory.read more
References
More filters
Journal ArticleDOI
Cancer is a Preventable Disease that Requires Major Lifestyle Changes
Preetha Anand,Ajaikumar B. Kunnumakara,Chitra Sundaram,Kuzhuvelil B. Harikumar,Sheeja T. Tharakan,Oiki S. Lai,Bokyung Sung,Bharat B. Aggarwal +7 more
TL;DR: Evidence that inflammation is the link between the agents/factors that cause cancer and the agents that prevent it is presented and evidence that cancer is a preventable disease that requires major lifestyle changes is provided.
Journal ArticleDOI
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong Wan Kim,Dong Wan Kim,Marcello Tiseo,Myung-Ju Ahn,Karen L. Reckamp,Karin Holmskov Hansen,Karin Holmskov Hansen,Sang-We Kim,Rudolf M. Huber,Howard West,Harry J.M. Groen,Maximilian Hochmair,Natasha B. Leighl,Scott N. Gettinger,Corey J. Langer,Luis Paz-Ares Rodríguez,Egbert F. Smit,Edward S. Kim,William M. Reichmann,Frank G. Haluska,David Kerstein,D. Ross Camidge +21 more
TL;DR: Brigatinib yielded substantial whole-body and intracranial responses as well as robust progression-free survival; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety.
Journal ArticleDOI
Targeting ALK: Precision Medicine Takes on Drug Resistance
TL;DR: This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms.
Journal ArticleDOI
Classification of anticancer drugs--a new system based on therapeutic targets.
TL;DR: The arrival of a great number of new antineoplastic agents has made it necessary to reclassify all of the classical chemotherapeutic agents.
Journal ArticleDOI
Stability-indicating HPLC method for posaconazole bulk assay.
TL;DR: The proposed method was successfully applied to posaconazole bulk quantification, showing the method is useful for determination of the drug in routine analysis.